Search

Your search keyword '"Chow, W."' showing total 135 results
Start Over Author "Chow, W." Publisher sage publications
135 results on '"Chow, W."'

4. Open-Label Phase 1B Pilot Study to Assess the Antiviral Efficacy of Simvastatin Combined with Sertraline in Chronic Hepatitis C Patients

Author

Eric Lawitz, Ralf Altmeyer, John G. McHutchison, Keyur Patel, Narinder Chopra, Hans L. Tillmann, John C.R. Randle, Chow W. Cheng, and Seng Gee Lim

Subjects
Adult, Male, Simvastatin, Genotype, Coenzyme A, Pilot Projects, Hepacivirus, Pharmacology, Reductase, Antiviral Agents, Drug Administration Schedule, Polyethylene Glycols, chemistry.chemical_compound, Text mining, Chronic hepatitis, Sertraline, Ribavirin, Humans, Medicine, Pharmacology (medical), Hypolipidemic Agents, Singapore, business.industry, Interferon-alpha, Hepatitis C, Chronic, Middle Aged, Recombinant Proteins, United States, In vitro, Infectious Diseases, chemistry, RNA, Viral, Drug Therapy, Combination, Female, Open label, business, Selective Serotonin Reuptake Inhibitors, Follow-Up Studies, medicine.drug
Abstract

Background 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors inhibit HCV replication in vitro. The combination of sertraline and simvastatin has synergistic antiviral activity in vitro, but there are no prior in vivo studies. Our aims were to prospectively assess the antiviral efficacy and safety of this drug combination in chronic hepatitis C (CHC) patients. Methods A total of 15 CHC adults (including 1 control subject) that were treatment-naive or prior partial responders/relapsers to standard-of-care therapy were enrolled at four centres (2 in Singapore and 2 in the US). Patients received simvastatin 40 mg once daily and sertraline 50 mg once daily for 7 days, and then 80 mg once daily and 100 mg once daily, respectively, for another 21 days with a 14-day follow-up. Results Of the 15 CHC patients, 13 completed the study. Subjects were mostly Caucasian (8/15), mean age 49.1 ±9 years and the genotype distribution was 1=10, 2=2 and 3=3. No subject discontinued dosing due to adverse events. Mean HCV RNA change from baseline was from -0.005 to -0.236 log10 IU/ml across study intervals. Three subjects had transient >1 log10 HCV RNA declines. No subject achieved >2 log10 HCV RNA decline. Conclusions The combination of sertraline and simvastatin is well-tolerated over the short-term, but has no significant antiviral or anti-inflammatory response in CHC patients. This may reflect in vivo differences in synergy between statin and/or selective serotonin reuptake inhibitors and incomplete inhibition of membrane protein prenylation with statin therapy.

Published
2011
Full Text
View/download PDF

49. Atrium Hot Smoke Tests in a Big Shopping Complex

Author

Chow, W., primary, Pang, Edgar, additional, Han, S., additional, Dong, H., additional, Zou, G., additional, Gao, Y., additional, Hou, Y., additional, He, Z., additional, Zou, J., additional, Li, K., additional, Leung, Victor, additional, and Yip, Eric, additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results